Why Is ALNYLAM PHARMACEUTIC (ALNY) Stock Down Today?
By the Top Tier Newswire AI Desk · August 27, 2026 at 10:23 AM ET · reviewed against 1 wire stories
ALNYLAM PHARMACEUTIC (ALNY) is down -3.11% in the latest session. Our newswire has captured 1 story on ALNY across 1 source in the last 36 hours, with AI sentiment reading mixed (avg 50/100).
Public view, delayed 4h. Every headline, price and sentiment read below — and this write-up itself — reaches Pro subscribers live. Public readers see it once it clears the delay.
ALNY stock closed down 3.11% at $231.56 on August 26, 2026, following a legal development that triggered a gap down in the session. The stock opened at $236.56, a 1.0% drop from the previous close, and continued to decline throughout the morning. The move appears linked to a new investor alert issued by Kirby McInerney LLP, which is investigating potential claims involving Alnylam Pharmaceuticals. The firm is representing shareholders and examining whether the company may have failed to disclose material information.
What Happened
Kirby McInerney LLP announced its investigation into Alnylam Pharmaceuticals, alleging potential investor claims. The law firm is seeking to represent shareholders who may have suffered losses due to alleged disclosures or omissions. This legal alert, issued on the same day trading began, likely contributed to the early sell-off. The stock traded as low as $231.01 before finishing the session at $231.56. The decline occurred despite recent positive coverage from analysts, including a BMO Capital initiation with an Outperform rating and a $318 price target, and Wells Fargo maintaining Equal-Weight with a revised $256 price target.
What The Data Shows
The stock opened with a 1.0% gap down and traded in a narrow range before closing lower. Volume was 0.3 million shares, which is 0.2 times the 3-month average, indicating limited participation. The stock remains within its 52-week range of $197.81 to $495.55. On August 27, the stock printed four fresh 52-week highs and nine fresh 52-week lows, highlighting its volatile price action. Insiders sold $1.1 million worth of shares in the last 90 days, with the most recent filing on June 3. Congressional trades in the same period included two buys and three sells, with recent activity by Donald J. Trump.
What To Watch
Investors should monitor the progression of the Kirby McInerney LLP investigation and any potential developments in the legal landscape. Analyst coverage remains largely positive, but the current stock price reflects a mix of optimism and caution.
AI-assisted analysis composed exclusively from headlines and data on the Top Tier newswire. Public view is delayed 4 hours from real time. Not financial advice.
NEW YORK, Aug. 26, 2026 (GLOBE NEWSWIRE) -- The law firm of Kirby McInerney LLP continues its investigation on behalf of Alnylam Pharmaceuticals, Inc....
Want the next move before the crowd? The live terminal streams every headline in real time with watchlist alerts, AI sentiment, and the full data stack behind this page.Get Pro Access →